Latest filing published 01 Sept 2026 for Goldline Pharmaceutical, €0.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Amol Laxmikant Mujumdar: trading record in brief
Amol Laxmikant Mujumdar discloses dealings in Goldline Pharmaceutical to SEBI (PIT + SAST). Activity is concentrated on a single trading day, 1 September 2026, with 2 filings.
Every open-market trade on record is a purchase: 2 purchases worth €0, and no sale. The totals do not cover 1 filing with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.
The record was last updated on 1 September 2026 with an open-market purchase (€0) in Goldline Pharmaceutical. Every figure here comes from the filings published by SEBI (PIT + SAST) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Amol Laxmikant Mujumdar
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 60,000 shares00.0000% mcap100.0% of flowEquityMarket PurchaseSEBI:0749c3e33cf4b5b03c17feaf459c3a73d97fbe84Canonical exit: 30 Nov 2026 (T+90)
- 18,000 shares0EquityMarket PurchaseSEBI:839eceb8e48056bc6b39926a18b9bd3120efa4cfCanonical exit: 30 Nov 2026 (T+90)
2 of 2 declarations